Tardive syndromes (TDS) typically manifest 3 months or later after exposure to antipsychotic drugs, and unfortunately have no satisfactory medical treatment. We explored the possibility of using therapeutic repetitive transcranial magnetic stimulation (rTMS). Twenty-six patients were allocated to receive real or sham rTMS over the hand/arm area of motor cortex (M1). Each received a daily total of 2000 rTMS pulses (20 Hz at 100% rMT: 1000 stimuli per hemisphere) for 10 consecutive days. Outcome was assessed using the Abnormal Involuntary Movement Scale (AIMS) and TMS measures of M1 excitability. Three patients in the sham group failed to complete the study. At baseline, there was no significant difference between the groups in age, sex distribution, duration of illness, AIMS score and drug treatment. rTMS improved symptoms in both groups. However, there was a greater reduction in the AIMS score of the real rTMS group compared with the sham group (real, 8.3 ± 1.7 points; sham 1.2 ± 3.3; repeated measure analysis ANOVA Time X Group interaction P = 0.001). The same trends were observed in the clinical subscales. Following treatment, MEP amplitudes at higher intensities (140, and 150%) increased more in the real treatment group than in the sham group. This is the first clinical trial study of bilateral hemispheric rTMS in patients with TDS and suggests that 20 Hz rTMS might be a feasible treatment option in patients unresponsive to "first-line" treatment. Clinical trial registration ClinicalTrials.gov Identifier: NCT03145311.
Introduction
Tardive syndrome (TDS) is a potentially permanent and irreversible hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents. DSM-5 diagnostic criteria for TDS include a history of more than 3 months cumulative exposure to dopamine receptor blocking agents (DRBAs), except in elderly patients in whom 1 month is adequate (American Psychiatric Association 2013). The causative agents are usually typical or atypical antipsychotic drugs (APDs). Recent reports, however, suggest that TDS could also be caused by a wide variety of psychotropic drugs, such as antidepressants and antiparkinsonian medications (Lerner and Miodownik 2011) . Tardive syndrome can manifest heterogeneous features of abnormal involuntary movements that comprise dystonia, chorea, athetosis, akathisia, myoclonus, stereotyped behavior, tremor, and tourettism or tics (Dauer et al. 1998; Aia et al. 2011; Lerner and Miodownik 2011; Aquino and Lang 2014) . Orofacial dyskinesia is the most common symptom in less severe cases, while generalized hyperkinetic movements with predominance of axial dystonia also occur in severe cases (Thobois et al. 2008 ). These abnormal movements can persist for years despite discontinuation of the offending drug. In many cases, TDS can be an irreversible condition, resistant to pharmacological treatment.
Although the pathophysiology of TDS is not well understood, it is hypothesized that central dopamine blockade 1 3 plays an important role. Striatal dopamine receptor supersensitivity has so far been the most plausible explanation for development of TDS. Chronic exposure to DRBAs can induce upregulation of postsynaptic dopamine receptors, particularly of the D2 subclass, in the striatum (Loonen and Ivanova 2013) . Teo et al. (2012) hypothesized that hypersensitivity of D2 receptors could cause maladaptive plasticity in cortico-striatal transmission, resulting in an inability to normalize the miscoded motor program in patients with TDS. Trugman et al. (1994) hypothesized that the D2 receptor blockade concomitant with repetitive activation of the D1 receptors could be a fundamental cause of TDS. This hypothesis might be consistent with the delayed onset of TDS after exposure to neuroleptics and the persistence of TDS even after withdrawal from them (Trugman et al. 1994 ). In addition, maladaptive changes in non-dopaminergic neurotransmitter systems, such as those involving opioids (enkephalin and dynorphin), glutamate, and acetylcholine, have also been reported in patients with TDS (Tsai et al. 1998) . Until the recent report of the KINECT3 trial (Hauser et al. 2017 ), which showed a significant effect of valbenazine, a drug that inhibits uptake of dopamine into synaptic vesicles, there were no satisfactory medical treatments.
Several recent reports have suggested that TDS can be treated with deep brain stimulation (DBS) within the basal ganglia (Nandi et al. 2002; Trottenberg et al. 2001 ) and open-labeled small case series (Franzini et al. 2005; Sako et al. 2008; Shaikh et al. 2014 ) have shown that GPi-DBS can have positive effects in intractable TDS, sometimes with immediate relief of symptoms.
Prospective studies with blind assessments have confirmed these reports and show that GPi-DBS can alleviate TDS symptoms regardless of their subtype (e.g., chorea and dystonia) or body distribution (Damier et al. 2007; PoucletCourtemanche et al. 2016) . It has also been noted that not only the GPi but also the STN and thalamus can be targets for DBS in the treatment of TDS (Zhang et al. 2006; Sun et al. 2007 ). These observations indicate that TDS might be a network disorder involving cortico-thalamo-basal ganglia motor circuitry, which would be consistent with the idea that TDS results from abnormal plasticity in the motor circuit that links cortex with basal ganglia (Thobois et al. 2008; Trugman et al. 1994 ).
The present study was prompted by our experience with a 24 year-old female patient admitted to our hospital with severe neuroleptic malignant syndrome. Symptoms had developed abruptly with hyperthermia (> 38 °C), mental status change, muscle rigidity, tremors, autonomic lability, with creatinine phosphokinase 2500. She received conventional treatment for neuroleptic malignant syndrome for 2 weeks. As a last option we applied 25 Hz rTMS bilaterally over M1 since this has been reported to be a useful option in Parkinson's disease (Lomarev et al. 2006; Khedr et al. 2006b ). After 5 sessions (1000 stimuli per hemisphere) per week for 4 weeks she showed a remarkable improvement (case report not published) with normal gait, normal CPK and normal temperature.
Based on this experience, and the concept that TDS may result from a disorder in a distributed motor network involving cortex and basal ganglia, the aim of the present study was to evaluate the therapeutic effect of repeated sessions of high frequency rTMS applied over motor area of both hemispheres for patients with drug induced TDS that are unresponsive to "first-line" treatment.
Materials and methods
According to the diagnostic and statistical manual of mental disorders, 5th edition (DSM V) (American Psychiatric Association 2013), the spectrum of TDS includes involuntary movements of the tongue, jaw, trunk, or extremities, and may be choreiform, athetoid, or stereotypic in nature. Inclusion criteria included: Abnormal movements appearing during exposure or within 4 weeks of withdrawal from oral antipsychotics or 8 weeks from depot formulations. The minimal exposure to antipsychotics was 3 months, except for patients older than 60, who developed TDS after using antipsychotic drugs for 1 month. The movements were present for at least 1 month to fulfil the criteria for TDS. Exclusion criteria: All contraindications for magnetic stimulation, (patients with magnetic or any other implanted device or patients with a history of seizure, severe dementia, intracranial lesion on neuroimaging) or associated systemic disease.
Based on the phenomenology, TDS was subtyped as: tardive dyskinesia, tardive stereotypy, tardive dystonia, tardive tremor, tardive akathisia, tardive myoclonus and tardive tourettism (Bhidayasiri and Boonyawairoj 2011) .
Thirty patients with drug induced TDS were recruited from the outpatient clinic of Aswan University Hospital. Four cases were excluded; 2 had history of epilepsy and another 2 had systemic disease (cardiac patients and has AF). The remaining 26 (14 males and 12 females, mean age 41.15 ± 16.8 years; range, 21-79 years) participated in the study. The duration of TDS was 18.35 ± 30.8 months ranging from 1 month to 120 months. All Patients stopped antipsychotic medication and received medical treatment in the form of amantadine, benztropine, clonazipame, Ginkgo biloba, baclofen, dopaminergic drugs, and dopamine agonist with unsatisfactory results. The duration of medical treatment for management of TDS was 6.06 ± 8.8 months. None of the patients suffered from any other clinically relevant disorders. They were randomly assigned to two groups; real (13 Patients) and Sham (13 patients). Each group received 10 sessions of rTMS. Three out of the sham group did not complete the study, and asked to be withdrawn after the 5th session (see flow chart Fig. 1 ). The previously diagnosed psychiatric disorders of the patients were as follows: 13 had schizophrenia, 10 had mood disorders. Fourteen patients had received both 1st and 2nd generation antipsychotic (Haloperidol 50 mg/ 2-4 weeks + Risperidone); 5 patients had received 1st generation antipsychotic (Haloperidol 50 mg/2-4 weeks); and 4 patients had received 2nd generation drugs (Risperidone and/or Aripiprazole). The duration of antipsychotic treatment ranged from to 12-30 months. Tardive dyskinesia (oro-bucco-lingual dyskinesia) was diagnosed in 11 patients, and tardive tremors, bradykinesia and rigidity were diagnosed in 12 patients. Demographic and clinical data of the two groups are given in Table 1 .
Each patient was assessed with the abnormal involuntary movement scale (AIMS) (Guy 1976) immediately before treatment and after the end of 10th session. The entire test can be completed in about 10 min. The AIMS test has a total of twelve items rating involuntary movements of various areas of the patient's body. These items are rated on a fivepoint scale of severity from 0 to 4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the 12 items refer to dental care. The remaining 10 items refer to body movements themselves. 13.5 ± 2.7 11.4 ± 3.7 0.20
Overall severity 2.9 ± 0.6 2.3 ± 0.7 0.42 Incapacitation 2.6 ± 0.5 2.0 ± 0.8 0.11 Awareness 2.6 ± 0.9 2.2 ± 0.8 0.31
Experimental setup and design
Subjects sat in a comfortable chair. Electromyographic (EMG) recordings (Nihon Kohden 9400, Japan) from the abductor digiti minimi muscle of right hand was acquired with silver-silver chloride surface electrodes, using a muscle belly-tendon set-up, with a 3-cm-diameter ground electrode placed on the wrist. Because the clinical symptoms were bilateral so we select the dominant hemisphere (left hemisphere) to be measured. The EMG parameters included a bandpass of 20-1000 Hz and a recording time window of 200 ms. TMS was performed with a 90-mm figure-of eight coil connected to Magstim (UK) super rapid magnetic stimulator. Motor thresholds (MT) were determined after localization of the motor "hot spot" for the abductor digiti minimi muscle in left hemisphere as described in previous reports (Khedr et al. 2006a (Khedr et al. , b, 2015 (Khedr et al. , 2016a . EMG signals were monitored and recorded for 20 ms before stimulation. RMT, AMT, cSP and iSP were evaluated as previously reported by Khedr et al. (2006a Khedr et al. ( , b, 2015 Khedr et al. ( , 2016a , and Werhahn et al. (2007) .
Randomization (parallel design)
All eligible participants were randomly assigned to one of the two groups using serially numbered closed, opaque envelopes. Each patient was given a serial number from a computer generated randomization table, and was placed in the appropriate group after opening the corresponding sealed envelope. Counseling for participation was conducted before recruitment. The 1st group received real 20 Hz-rTMS at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), and the 2nd group received sham stimulation with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
Repetitive transcranial magnetic stimulation (rTMS) procedure
TMS was performed with a commercially available 70 mm figure of eight coil connected to a high frequency Magstim stimulator. The primary motor areas of the hand of both hemispheres were determined as previously reported (Khedr et al. 2006a (Khedr et al. , b, 2015 . Because all patients had bilateral rigidity and/or tremors or Oro-Bucco-lingual dyskinesia which is controlled by both hemispheres (bilaterally represented in the cortex), we applied the rTMS over the right and left hand area consecutively. During rTMS, all patients wore ear plugs in to protect the ears from the acoustic artifact associated with the discharge of the stimulation coil.
For each patient 10 sessions were administered once per day for 5 consecutive weekdays each week for 2 weeks. All patients were assessed before rTMS and immediately after the end of the 10 sessions by a doctor who was blinded to treatment type. None of the patients had rTMS before, and therefore, they were unaware of the type of stimulation they had received.
Follow up
The AIMS scale and different parameters of cortical excitability were assessed before and after the end of session treatment. The primary outcome was change in AIMS score at the end of the last session and then one month after treatment. Secondary outcome was change in cortical excitability parameters immediately (within 20 min) after the last session of treatment. All patients provided fully informed consent. The local ethics committee of Aswan University had approved the experimental protocol.
Statistical analysis
Baseline values (ie, before rTMS) of the age, duration of extrapyramidal, duration of treatment and AIMS scale and its sub items in each group were compared using non-parametric Mann-Whitney test and for categorical variables Chi-Square was used. Means ± standard deviation (SD) were used to represent data. The level of significance was set at P < 0.05. Changes in AIMS in the two groups overtime were analysed with a two factor repeated -measures analysis of variance (ANOVA) with "treatment" (between subjects variable: real versus sham rTMS) and "time" (within subjects variable: before, versus after the end of last treatment session), as the main factors. Changes in MEPs were analysed using a three-way ANOVA with "treatment" (real versus sham rTMS) "intensity" (110, 120, 130, 140 , 150% of resting motor threshold) and "time" (before, versus after the end of last treatment session), as the main factors. When necessary, a Greenhouse-Geisser correction was applied to correct for non-sphericity.
Results
At baseline, there was no significant difference between the groups in age, sex distribution, duration of illness, and treatment. The offending antipsychotic drugs that induced TS and the current treatment were similar in both groups. The mean value ± SD of AIMS and their sub-items (overall severity), incapacitation and awareness were similar with no significant differences between both groups (Table 1) . There were no significant differences between groups in any of the neurophysiological parameters including rTMT, AMT, cSP at different intensities, Input-output curve and iSP (Table 2) .
No one able to distinguish sham from real rTMS may be because the intensity of stimulation at the level of motor threshold.
There was a significant improvement in the AIMS score in the real rTMS group compared with the sham group. The AIMS in the real group decreased by a mean of 8.3 ± 1.7; P = 0.0001, while in sham group there was a much smaller reduction of 1.2 ± 3.3 points (P = 0.03). The repeated-measures ANOVA that showed a significant Time (pre, post-session) × Group (real versus sham) interaction (Df = 1(21), F = 46.6, P = 0.0001), indicating that the reduction in the real group was greater than that in the sham group. The same trend was observed in all the subscales (overall severity, incapacitation, and awareness) with significant improvement in real group while there were no significant changes in the sham group (Table 3 ; Fig. 2 ).
There were no significant changes in cortical excitability (RMT, AMT, TCI) in any group. This was confirmed in a repeated-measures ANOVA that showed no significant Time (pre-and post-session) × Group (real versus sham) interaction and no main effect of Time (Table 4) . Following treatment, MEP amplitudes at higher intensities (140, and 150%) increased more in the real treatment group than in the sham group. There were no significant changes in CSP in either group (Table 5 ; Fig. 3 ). 
Discussion
The main finding in the present study was the clear effect of high frequency rTMS in ameliorating the symptoms of TDS in a group of patients who were unresponsive to "first-line" treatment. It is the first clinical trial to suggest that rTMS may offer a possible treatment for TDS. Our trial was inspired by our serendipitous experience in treating a single case of TDS with high frequency rTMS. We can, therefore, only speculate on the mechanism of action of rTMS in the present patients. Neurolepticinduced extrapyramidal syndromes may result primarily from blockade of dopamine receptors in the striatum, leading to imbalance between acetylcholine and dopamine systems in this area. Some reports in the literature show that high frequency rTMS can transiently increase levels of dopamine in the basal ganglia (Franzini et al. 2005; Sako et al. 2008; Werhahn et al. 2007 ). However, this might be more likely to exacerbate symptoms than to control them since recommended treatments such as valbenazine reduce rather than increase dopamine availability. One remote possibility might be that regular pulsatile increases in dopamine levels induced by each rTMS session, can gradually reverse the long-term changes induced by dopamine receptor blockade. But there is no proof that this would be the case.
An alternative explanation is that, as reviewed in the Introduction, TDS may result from abnormal functioning of a distributed motor network involving basal ganglia and motor cortex. Over time, neuroleptic-induced changes in basal ganglia output could lead to plasticity in Fig. 2 The mean values of abnormal involuntary movement score (AIMS) pre and post-sessions and the sub items scores in real and sham groups of tardive syndromes. There were significant improvements in real group, while no such changes were observed in the sham group in total AIMS and sub items (overall severity, incapacitation and awareness) 31.9 + 5.8 32.9 ± 7.0 NS the connections within this system. Such plasticity could also be influenced directly by an interaction of neuroleptic drugs with the function of NMDA receptors which play a critical role in synaptic plasticity (Teo et al. 2012) . The resulting maladaptive plasticity would then be similar to that observed in many other hyperkinetic movement disorders. In this case, rTMS could influence motor cortex plasticity and gradually restore a more balanced level of activity in the motor loop after several days of treatment.
Conclusion and recommendation
Bilateral hemispheric high frequency rTMS might be a feasible treatment for patients with tardive syndromes unresponsive to "first-line" medical treatment; further multicenter studies are needed to confirm this result. In particular, it is important to clarify specific inclusion criteria for patient selection and the optimal stimulation parameters as well as to increase the duration of follow-up. 
